What if Moderna Doesn't Win the Coronavirus Vaccine Race?

Moderna and rival Pfizer expect phase 3 safety readouts later this month.
Pfizer this week said interim phase 3 efficacy data show its vaccine candidate was more than 90% effective.
Moderna hasn't yet reported phase 3 efficacy data.